Wrapping up their ESMO Congress 2024 coverage with a discussion of renal cancer, our hosts talk about what strategies work (or don’t) after frontline therapy for mRCC, implications on adjuvant therapy, as well as major efforts for non-clear cell histologies like the SUNNIFORECAST trial.

The View on GU with Lalani & Wallis integrates key clinical data from major conferences and high impact publications, sharing meaningful take home messages for practising clinicians in the field of genitourinary (GU) cancers. Learn more about The View on GU: theviewongu.ca

This podcast has been made possible through unrestricted financial support by Astellas, AstraZeneca, Bayer, Bristol Myers Squibb, Eisai, Ipsen, J&J Innovative Medicine, Merck, Novartis, Pfizer, TerSera.

In the second episode of our ESMO Congress 2024 series, our hosts discuss both non-muscle invasive and muscle-invasive bladder cancer, along with other data that impacts the spectrum of urothelial cancer diagnosis and treatment.

The View on GU with Lalani & Wallis integrates key clinical data from major conferences and high impact publications, sharing meaningful take home messages for practising clinicians in the field of genitourinary (GU) cancers. Learn more about The View on GU: theviewongu.ca

This podcast has been made possible through unrestricted financial support by Astellas, AstraZeneca, Bayer, Bristol Myers Squibb, Eisai, Ipsen, J&J Innovative Medicine, Merck, Novartis, Pfizer, TerSera.

In the first episode of this three-part series focused on the presentations and findings from the ESMO Congress 2024, our hosts focus on mCSPC prostate cancer treatment advancements, including lutetium PSMA, darolutamide and much more.

The View on GU with Lalani & Wallis integrates key clinical data from major conferences and high impact publications, sharing meaningful take home messages for practising clinicians in the field of genitourinary (GU) cancers. Learn more about The View on GU: theviewongu.ca

This podcast has been made possible through unrestricted financial support by Astellas, AstraZeneca, Bayer, Bristol Myers Squibb, Eisai, Ipsen, J&J Innovative Medicine, Merck, Novartis, Pfizer, TerSera.

Building on Episode 12, which focused on primary treatment for prostate cancer, Drs. Loblaw, Lalani and Wallis move on to discuss post-op treatments, including the evolution of post-operative radiotherapy and the shift from adjuvant therapy to early salvage therapy.The View on GU with Lalani & Wallis integrates key clinical data from major conferences and high impact publications, sharing meaningful take home messages for practising clinicians in the field of genitourinary (GU) cancers. Learn more about The View on GU: https://theviewongu.com

This podcast has been made possible through unrestricted financial support by Astellas, AstraZeneca, Bayer, Bristol Myers Squibb, Eisai, Ipsen, Merck, Novartis, Pfizer and TerSera

Dr. Andrew Loblaw (Radiation Oncologist (Sunnybrook Research Institute), Clinician Scientist, and dual Professor in the Department of Radiation Oncology and the Institute of Health Policy Management & Evaluation at the University of Toronto) takes time out of the busy 2024 Canadian Urological Association Annual Meeting schedule to chat with Dr. Aly-Khan Lalani and Dr. Christopher Wallis. Dr. Loblaw provides an overview of how he treats his patients, including shifting to hypofractionation, brachytherapy boosts and more. Keep an eye out for Episode 13, which is the second and final part of this mini-series!

This podcast has been made possible through unrestricted financial support by Astellas, AstraZeneca, Bayer, Bristol Myers Squibb, Eisai, Ipsen, Merck, Novartis, Pfizer and TerSera.

The View on GU with Lalani & Wallis integrates key clinical data from major conferences and high impact publications, sharing meaningful take home messages for practising clinicians in the field of genitourinary (GU) cancers. Learn more about The View on GU: https://theviewongu.com

Dr. Lalani and Dr. Wallis cover the utility of metformin, quality of life analyses, and optimizing treatment approaches for resistant prostate cancer, including the place for radioligand therapies.The View on GU with Lalani & Wallis integrates key clinical data from major conferences and high impact publications, sharing meaningful take home messages for practicing clinicians in the field of genitourinary (GU) cancers.

Learn more about The View on GU: https://theviewongu.com

This podcast has been made possible through financial support by Astellas, AstraZeneca, Bayer, Bristol Myers Squibb, Eisai, Ipsen, Merck, Novartis, Pfizer and TerSera.

Our hosts start by discussing the 901 trial before moving into a discussion about bladder preservation and the importance of being multi-disciplinary.The View on GU with Lalani & Wallis integrates key clinical data from major conferences and high impact publications, sharing meaningful take home messages for practicing clinicians in the field of genitourinary (GU) cancers.

Learn more about The View on GU: https://theviewongu.com

This podcast has been made possible through financial support by Astellas, AstraZeneca, Bayer, Bristol Myers Squibb, Eisai, Ipsen, Merck, Novartis, Pfizer and TerSera.

The View on GU with Lalani & Wallis integrates key clinical data from major conferences and high impact publications, sharing meaningful take home messages for practicing clinicians in the field of genitourinary (GU) cancers.

Learn more about The View on GU: https://theviewongu.com

This podcast has been made possible through financial support by Astellas, AstraZeneca, Bayer, Bristol Myers Squibb, Eisai, Ipsen, Merck, Novartis, Pfizer and TerSera.